These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33078727)

  • 41. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
    Wu IC; Wu DC; Hsu PI; Lu CY; Yu FJ; Wang TE; Chang WH; Chen JJ; Kuo FC; Wu JY; Wang WM; Bair MJ
    Helicobacter; 2007 Dec; 12(6):633-7. PubMed ID: 18001406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
    J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
    Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
    Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
    De Francesco V; Ridola L; Hassan C; Bellesia A; Alvaro D; Vaira D; Zullo A
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):147-50. PubMed ID: 27308644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
    He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
    Dig Dis Sci; 2022 Jan; 67(1):208-215. PubMed ID: 33559090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.
    Sezgin O; Aydın MK; Özdemir AA; Kanık AE
    Turk J Gastroenterol; 2019 May; 30(5):420-435. PubMed ID: 31060997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
    Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
    Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
    Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
    Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
    Alhalabi M; Alassi MW; Alaa Eddin K; Cheha K
    BMC Infect Dis; 2021 Jul; 21(1):642. PubMed ID: 34218802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
    Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice.
    Liang CM; Cheng JW; Kuo CM; Chang KC; Wu KL; Tai WC; Chiu KW; Chiou SS; Lin MT; Hu TH; Chuah SK
    Biomed J; 2014; 37(5):326-30. PubMed ID: 25163495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
    Silva FM; Queiroz EC; Navarro-Rodriguez T; Barbuti RC; Mattar R; Iriya K; Lee JH; Eisig JN
    Clinics (Sao Paulo); 2015 May; 70(5):318-21. PubMed ID: 26039946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial.
    Zhou L; Zhang J; Chen M; Hou X; Li Z; Song Z; He L; Lin S
    Am J Gastroenterol; 2014 Apr; 109(4):535-41. PubMed ID: 24642580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
    Yun JW; Wang C; Yu Y; Xu HM; Gou LZ; Li XL; Yi GR; Lin YM; Han TY; Zhang DK
    Br J Clin Pharmacol; 2023 Jan; 89(1):232-241. PubMed ID: 35947524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.
    Chen LW; Chien RN; Chang JJ; Fang KM; Chang LC
    Int J Clin Pract; 2010 Oct; 64(11):1530-1534. PubMed ID: 20846200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
    Huang TH; Yang SC; Tai WC; Liang CM; Kuo CM; Yao CC; Wu CK; Kuo YH; Chou YP; Lee CH; Wu KL; Chuah SK
    Biomed J; 2021 Dec; 44(6 Suppl 2):S275-S281. PubMed ID: 35292265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.
    Paoluzi OA; Del Vecchio Blanco G; Visconti E; Coppola M; Fontana C; Favaro M; Pallone F
    World J Gastroenterol; 2015 Jun; 21(21):6698-705. PubMed ID: 26074708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.